Navigation Links
Icahn School of Medicine at Mount Sinai awarded $2.7 million from NIH to investigate novel therapy for eczema
Date:11/25/2013

The National Institutes of Health has awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate to severe atopic dermatitis (AD), also known as eczema. Currently, no treatments are available that achieve long-term remission without difficult side effects for this debilitating skin disorder, characterized by inflammation, severe itching, and a rash that can adversely affect many aspects of everyday life.

The team will investigate the efficacy of a new intravenous medication, ILV-094, which blocks IL-22, an important protein that has been shown in animal models to trigger epidermal growth and differentiation abnormalities and chronic inflammation, which are major features of AD. The researchers see the study as potentially groundbreaking in using "narrow pathway"-targeted immune interventions for not just AD, but other "allergic" inflammatory diseases of the skin or other organs, such as asthma.

At the Icahn School of Medicine at Mount Sinai, Emma Guttman, MD, PhD, Associate Professor of Dermatology, and Director of the Laboratory for Inflammatory Skin Diseases, and Mark Lebwohl, MD, Professor and Chair of Dermatology, will lead the study. James G. Krueger, MD, PhD, D. Martin Carter Professor and head of the Laboratory for Investigative Dermatology at The Rockefeller University, will oversee the mechanistic studies for the trial. Dr. Guttman has a joint appointment at Rockefeller and will conduct clinical and mechanistic studies at both institutions.

Dr. Guttman was the first investigator to show in humans that a separate population of T cells secrete interleukin 22 (IL-22) and she also discovered the importance of the Th22 pathway and IL-22 in AD.

"Dr. Guttman has been at the forefront of many of the most important strides in understanding the pathophysiology of atopic dermatitis," said Dr. Lebwohl. "This trial is an important step in developing safer treatments for patients with moderate to severe AD."

"I hope that this research results in a final proof of concept and a novel treatment for AD without side effects," said Dr. Guttman. The clinical trial is expected to last five years. The majority of the clinical trial, will be conducted at the Icahn School of Medicine at Mount Sinai.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Icahn School of Medicine at Mount Sinai Honors Innovators in Scientific Research and Health Care Philanthropy at 2013 Commencement Ceremony
2. Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh to Collaborate on Clinical Studies for Mucopolysaccaridoses
3. Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration
4. Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles
5. World-Renowned Gastroenterologist Jean-Frédéric Colombel, MD, Joins the Icahn School of Medicine at Mount Sinai
6. Janina A. Longtine, MD of the Icahn School of Medicine at Mount Sinai Elected President of the Association for Molecular Pathology
7. A Best Manuscript Award Goes to the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai
8. A Best Manuscript Award goes to Icahn School of Medicine at Mount Sinai
9. Four Researchers from Icahn School of Medicine at Mount Sinai Among the 400 Most Highly Influential Biomedical Researchers in the World
10. Even Preschoolers View the Overweight Negatively
11. Catastrophic Head Injuries to High School Football Players Rising
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, has ... Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 A.Y. ... line up exactly with Bible Prophecy – a protected way for those who will ...
(Date:12/2/2016)... ... December 02, 2016 , ... On November 24th, 2016, Thanksgiving ... eight different sites throughout Miami-Dade and Broward counties. This is the largest meal ... on Thanksgiving morning by putting together individual meals via assembly lines and passing ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 ... the National Family Partnership and the Drug Enforcement Administration as part of the National ... the 10 winning schools who decorated their campuses with this year’s Red Ribbon Week ...
(Date:11/30/2016)... ... November 30, 2016 , ... "I hate when the ... while brushing my teeth," said an inventor from Bridgewater, N.J. "I thought that there ... this handy device." , He developed the patent-pending DEFLECTOR to prevent saliva and toothpaste ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... mental health treatment has announced the opening of a new residential mental health ... girls with mental health issues such as severe anxiety, depression, bi-polar disorder, and ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... CVS Health Corporation (NYSE: CVS ... City on Thursday, December 15, 2016, beginning at 8:00 a.m. (ET). Senior ... an in-depth review of the company,s strategies to drive ... also discuss 2017 earnings guidance during the event. ... will be broadcast simultaneously on the Investor Relations portion ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
(Date:12/2/2016)... , December 2, 2016 On ... down 1.36%; the Dow Jones Industrial Average edged 0.36% higher, ... 2,191.08, down 0.35%. Losses were broad based as six out ... has initiated research reports on the following Services equities: Myriad ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology: